Ciprofloxacin targets bacterial DNA replication and repair. It achieves this by inhibiting two crucial enzymes: topoisomerase II (DNA gyrase) and topoisomerase IV.
- DNA gyrase: This enzyme unwinds supercoiled DNA, allowing for replication and transcription. Ciprofloxacin binds to DNA gyrase, preventing it from relaxing the DNA supercoils. This stalls DNA replication and ultimately leads to cell death. Topoisomerase IV: This enzyme separates replicated DNA circles during bacterial cell division. Ciprofloxacin’s inhibition of topoisomerase IV prevents this separation, resulting in cell death.
The specific binding of ciprofloxacin to these enzymes is influenced by its chemical structure. The fluoroquinolone ring system interacts directly with the enzyme’s active site. Minor structural changes in the molecule can significantly alter its potency and spectrum of activity against various bacterial strains.
Bacterial susceptibility varies. Gram-negative bacteria, generally possessing higher levels of these topoisomerases, are often more sensitive than Gram-positive bacteria. Resistance mechanisms exist. Mutations within the topoisomerase genes themselves are a common route to resistance development. Other mechanisms include decreased drug uptake or increased drug efflux from the bacterial cell.
Understanding this mechanism is crucial for appropriate antibiotic selection and for managing the growing problem of antibiotic resistance. Careful consideration of bacterial susceptibility testing and patient-specific factors is paramount for effective treatment.
